Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Twitter Rx Drug Promos: FDA Studies Best Way To Convey Risk Info

Executive Summary

Agency to assess whether individuals have greater retention of risk information if it is included directly in online communications with limited character space rather than via a link.

You may also be interested in...



Twitter Promo Study Gets Tweaks, But FDA Rejects Many Industry Suggestions

Lilly recommended testing use of embedded Twitter cards to convey safety information and PhRMA proposed studying a universal graphic symbol or FDA's logo.

Rx Ad Studies Target Risk Info Location, Efficacy Framing, Oncology Products

Flurry of new studies brings tally of FDA research projects on Rx drug promotion to 43; the 14 in progress and 7 pending peer review or recently published have a total cost of $15.5m.

TV Drug Advertising Study Targets Those With Limited Or No Internet Use

US FDA will assess value of including 1-800 number and print ad in broadcast commercials; it is among 42 direct-to-consumer studies the agency has undertaken, 13 of which are in progress.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel